Reprocyc® ParvoFLEX gets EMA authorisation

The European Commission has granted Boehringer Ingelheim marketing authorisation for Reprocyc® ParvoFLEX, a new vaccine to protect swine foetuses against trans placental infection caused by porcine parvovirus, which BI is now launching in certain EU countries. The new vaccine is a subunit vaccine based on a more recent isolate from 2001 (strain 27a) that uses a manufacturing technology of baculovirus expression system to express one region of the virus (VP2 region) where most of the immune response is targeted. It can be mixed and administered with Reprocyc® PRRS EU, a vaccine for active immunization of breeding females affected with European Porcine Reproductive and Respiratory Syndrome. As it is approved for use at any stage of gestation and lactation, it can be introduced to the current PRRS control programs of sow herds.
Xavier de Paz Solanes, BI’s Global Brand Manager, said: “With this new product, veterinarians and producers can simultaneously control two of the most prevalent reproductive diseases in swine herds,” and Martin Forchieri, Marketing Head of Swine Strategic Business Unit, said: “I am really proud we continuously bring innovation to the market and keep addressing our customers’ needs.”